Please use this identifier to cite or link to this item:
|Title:||CD137L- DENDRITIC CELLS HAVE A NOVEL INFLAMMATORY PHENOTYPE AND INDUCE A POTENT TC1 RESPONSE AGAINST EPSTEIN-BARR VIRUS||Authors:||BHUSHAN DHARMADHIKARI||Keywords:||Dendritic cells, CD137 ligand, Immunotherapy, Cancer||Issue Date:||28-Apr-2017||Citation:||BHUSHAN DHARMADHIKARI (2017-04-28). CD137L- DENDRITIC CELLS HAVE A NOVEL INFLAMMATORY PHENOTYPE AND INDUCE A POTENT TC1 RESPONSE AGAINST EPSTEIN-BARR VIRUS. ScholarBank@NUS Repository.||Abstract:||Most clinical studies with dendritic cells (DCs) as anti-cancer vaccines have relied on GM-CSF + IL-4 derived cDCs. Although proven to be safe, the overall clinical benefits are low. These disappointing results are largely due the inability of cDCs to mount sufficiently strong T cell responses. In this study, we show that CD137L-DCs, generated via CD137L signaling, have a novel inflammatory phenotype and are closely related to in-vivo DCs. CD137L-DCs induce more potent CD8+ T cell response against cancer-associated Epstein-Barr virus and enhance the physiological of fitness of T cells. We thus report, CD137L-DCs as the next generation DCs for DC based immunotherapy. A phase I trial for treatment of Nasopharyngeal carcinoma (NCT03282617) is currently underway.||URI:||http://scholarbank.nus.edu.sg/handle/10635/138214|
|Appears in Collections:||Ph.D Theses (Open)|
Show full item record
Files in This Item:
|Dharmadhikari B.pdf||2.17 MB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.